Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CBLB | Q13191 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29049786 | 0.87 | PIM1 (0.42) | PIM1KDM4EALOX15TSHRACMSD | |
| SCHEMBL9298348 | 0.87 | PIM1 (0.42) | PIM1KDM4EALOX15TSHRACMSD | |
| SCHEMBL23491120 | 0.85 | PIM1 (0.45) | PIM1KDM4EALOX15TSHRACMSD | |
| SCHEMBL27830227 | 0.84 | KDM4E (0.41) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL12658771 | 0.82 | ALDH1A1 (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL100967 | 0.82 | KDM4E (0.61) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL21883573 | 0.82 | PIM1 (0.39) | PIM1KDM4EALOX15TSHRACMSD | |
| SCHEMBL22234567 | 0.81 | PIM1 (0.43) | PIM1KDM4EALOX15TSHRACMSD | |
| SCHEMBL29444559 | 0.81 | PIM1 (0.43) | PIM1KDM4EALOX15TSHRACMSD | |
| SCHEMBL12553244 | 0.81 | KDM4E (0.39) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | claimed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | claimed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | claimed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4143195-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-11028068-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200207737-A1 | SOMATASTATIN MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-07-02 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1799647-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| EP-1696915-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | Pfizer, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006037501-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2005060963-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | PFIZER INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | PIM1 3355/4885KDM4E 4554/4885ALOX15 2176/4885 |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD11B2 | PIM1 3477/4885KDM4E 1422/4885ALOX15 626/4885 |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | PIM1 3355/4885KDM4E 4554/4885ALOX15 2176/4885 |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B11, HSD11B2 | PIM1 3583/4885KDM4E 2116/4885ALOX15 475/4885 |
| US-20200207737-A1 | SOMATASTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | PIM1 4052/4885KDM4E 4683/4885ALOX15 1910/4885 |
| US-11028068-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | PIM1 3355/4885KDM4E 4554/4885ALOX15 2176/4885 |
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | PIM1 3355/4885KDM4E 4554/4885ALOX15 2176/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | PIM1 3355/4885KDM4E 4554/4885ALOX15 2176/4885 |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | PIM1 3355/4885KDM4E 4554/4885ALOX15 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.